Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials.

Vanita R ArodaJuan Pablo FriasLi-Nong JiElisabeth NiemoellerMy-Liên Nguyên-PascalKarl DenkelMelanie EspinasseHailing GuoSeungJae BaekJaeDuk ChoiIldiko Lingvay

Published in: Diabetes, obesity & metabolism (2023)

reduction and showed numerically greater improvements than placebo in glycaemic control and body weight, with safety consistent with the GLP-1 RA class. This article is protected by copyright. All rights reserved.

Keyphrases

body weight
type diabetes
resting state
functional connectivity
rheumatoid arthritis
glycemic control
cardiovascular disease
insulin resistance
clinical trial
randomized controlled trial
metabolic syndrome
double blind
systemic lupus erythematosus
phase iii
open label